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Pancreatic cancer is a complex, aggressive, and heterogeneous malignancy driven by
the multifaceted interactions within the tumor microenvironment. While it is known that
the tumor microenvironment accommodates many cell types, each playing a key role
in tumorigenesis, the major source of these stromal cells is not well-understood. This
review examines the contribution of bone marrow-derived cells (BMDC) to pancreatic
carcinogenesis, with respect to their role in constituting the tumor microenvironment.
In particular, their role in supporting fibrosis, immunosuppression, and neovascularization
will be discussed.
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INTRODUCTION
It is long known that adult stem cells have remarkable flexibility in
their differentiation repertoires. This plasticity allows adult stem
cells, particularly those of bone marrow origin, to engraft alterna-
tive non-haematopoietic locations and differentiate into cell types
appropriate to their new niche. This is particularly evident when
the recipient organ is damaged (Poulsom et al., 2002; Alison et al.,
2006). Bone marrow derived cells (BMDC) can either engraft or
fuse to adopt, or be reprogrammed, to the differentiated state of
the particular epithelia (Jang et al., 2004) [reviewed in (Herzog
et al., 2003)]. This suggests that the endogenous stem cell of an
organ is not confined to each specific organ but may be a dynamic
system involving circulating BMDC with stem cell niche environ-
ments regulating recruitment, proliferation, and differentiation
(Alison et al., 2006; Diaz-Flores et al., 2006). This may have sig-
nificant implications concerning the evolution of cancers inmany
solid organs, including the pancreas.
Much debate has loomed as to the questionable functional sig-
nificance of BMDC that have differentiated into epithelial cells
of solid organs (Krause et al., 2001; Wagers et al., 2002; Bruscia
et al., 2006), while very few studies have investigated this phe-
nomenon in the pancreas (Wang et al., 2006; Marrache et al.,
2008). Most studies have focused on restoring endocrine function
following islet cell injury (Choi et al., 2003; Hess et al., 2003; Ianus
et al., 2003; Lechner et al., 2004; Mathews et al., 2004; Taneera
et al., 2006; Hasegawa et al., 2007; Gao et al., 2008b), with few
studies assessing the contribution of BMDC to the exocrine pan-
creas, in particular in pancreatic cancer (Pan et al., 2009; Scarlett
et al., 2011). Wang et al. (2006) describe the contribution of
BMDC to pancreatic duct formation in neonatal mice, Marrache
et al. (2008), andWatanabe et al. (2009) demonstrate that BMDC
contribute to the pancreatic stellate cell (PSC) population in
chronic pancreatitis, while Pan et al. (2009) and Scarlett et al.
(2011) identified a contribution of BMDC to the PSC population
in rat and mouse models, respectively, of chemical carcinogenesis
of the pancreas.
It is well-established that the pancreatic tumor microenvi-
ronment plays an integral role in driving pancreatic carcino-
genesis and metastases, with the contribution of components of
the pancreatic tumor microenvironment, such as PSC, myofi-
broblasts/fibroblasts, and inflammatory cells, reviewed elsewhere
within this edition (Erkan et al., 2012; Evans and Costello,
2012). As such, this review will focus specifically on the con-
tribution of BMDC in pancreatic carcinogenesis. In partic-
ular the significant role that BMDC has within the tumor
microenvironment, and its implications for supporting pan-
creatic carcinogenesis, will be discussed. Table 1 and Figure 1
summarize the contribution of BMDC to the pancreatic tumor
microenvironment.
CONTRIBUTION OF BMDC TO EPITHELIAL TUMOR CELLS
A novel paradigm of epithelial cancer development was postu-
lated following the early investigations of Houghton et al. (2004),
where in amodel ofHelicobacter felis induced gastric carcinogene-
sis, the development of metaplasia and dysplasia was linked to the
engraftment and expansion of the BMDC population, eventually
giving rise to gastric adenocarcinoma (Houghton et al., 2004). It
was thus hypothesized that in response to tissue damage, BMDC
could migrate to and lodge in the stem/progenitor cell niche,
expand as a clonal unit and repopulate the epithelium, and that
mutations in these engrafted BMDC then lead to carcinogenesis
[reviewed in (Alison et al., 2006)].
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Table 1 | Summary of bone marrow derived cell contribution to the pancreatic tumor microenvironment.
BMDC type Contribution to pancreatic tumor microenvironment References
Myofibroblasts/fibroblasts Contribution to myofibroblast/fibroblast populations within the pancreatic
insulinoma, particularly at the tumor margin.
Circulating fibrocytes derived from BMDC and contributed to pancreatic fibrosis by
differentiating into collagen-producing myofibroblasts.
Direkze et al., 2004
Lin et al., 2012
Pancreatic stellate cells (PSC) Contribution to early stages of fibrosis, and produced the growth factors PDGF and
TGFβ1.
Significant contribution to the activated PSC population, occurring early in pancreatic
carcinogenesis. Express genes characteristic of peritumoral stellate cells compared
to those not associated with malignancy.
Akita et al., 2012
Scarlett et al., 2011
Myeloid-derived suppressor
cells (MDSC)
Immunosuppressive cell type within the stroma. Increased MDSC in the bone
marrow, peripheral circulation, and tumor. Inhibition reduces intra-tumoral accumu-
lation and prevents tumor growth.
Porembka et al., 2012
Mast cells Immunosuppressive cell type within the stroma. Migration to the tumor microenvi-
ronment is an early event in carcinogenesis and is necessary for tumor growth.
Chang et al., 2011
Fibroblast activating protein
(FAP) +ve cells
Immunosuppressive cell type within the stroma. Abrogation of FAP expression
arrests pancreatic tumor growth.






BM-derived endothelial progenitor cells (EPC) stimulate neovascularization and
pancreatic cancer growth, via the CXCL5/CXCL8/CXCR2 axis. CXCR2 in particular
was required for BM-derived EPC mobilization during pancreatic tumor growth.
BM-derived mesenchymal stem cells (MSC) contribute to neovascularization by
migrating to fast growing tumors and incorporating into blood vessels as atypical
VEGF-secreting endothelial cells.
BM-derived pro-angiogenic cells are targets for Shh derived from the pancreatic
tumors. Hh blockade disrupts tumor angiogenesis mediated through the impaired
interaction BMDC with the neovasculature. Responsible for VEGF-independent
neovascularization in pancreatic cancer.
Li et al., 2011
Beckermann et al., 2008
Nakamura et al., 2010;
Mizukami, 2012
Only a representative selection of published data presented here.
BMDC, bone marrow-derived cells; PDGF, platelet-derived growth factor; TGFβ1, transforming growth factor beta 1; PSC, pancreatic stellate cells; MDSC,
myeloid-derived suppressor cells; FAP, fibroblast activation protein-α; EPC, endothelial progenitor cells; CXCL5, epithelial neutrophil-activating peptide-78/chemokine;
CXCL8, interleukin 8; CXCR2, interleukin 8 receptor β/chemokine receptor; MSC, mesenchymal stem cells; VEGF, vascular endothelial growth factor; Shh, sonic
hedgehog; Hh, hedgehog.
Studies of the exocrine pancreas have failed to provide evi-
dence for differentiation of BMDC into epithelial tumor cells
directly. Pan et al. (2009) demonstrated in a rat model of carcino-
genesis that BMDC could modulate pancreatic cancer growth via
incorporation into the microenvironment, specifically the PSC
within the stroma (Pan et al., 2009). These findings were strength-
ened in a more recent study by Scarlett et al. (2011), who also
demonstrated a significant contribution of BMDC to the peri-
tumoral stroma in a mouse model of pancreatic carcinogenesis
(Scarlett et al., 2011). These data suggest that while BMDC do not
contribute directly to pancreatic epithelial tumorigenesis, they
play a significant and supportive role in promoting carcinogene-
sis via interactions within the tumor microenvironment. This will
be discussed in more detail below.
BMDC AND THE TUMORMICROENVIRONMENT
There is increasing evidence that the tumor microenvironment
influences tumor proliferation and survival, metastasis, resistance
to therapy and escape from immune control [reviewed in (Feig
et al., 2012)]. The desmoplastic stroma associated with pancre-
atic cancer is made up of a heterogeneous population of cells
including immune cells, stellate cells, blood vessels, extracellu-
lar matrix (ECM), fibroblasts, and myofibroblasts. However, the
major source of pancreatic stromal cells is not well-understood.
While conversion of resident cells within normal tissue stroma are
obvious candidates, increasing evidence is emerging that BMDCs
are a source of non-resident stromal cells that contribute signifi-
cantly to the stroma, and thus aid in the progression and invasion
of pancreatic malignancy (Luo et al., 2012).
CONTRIBUTION OF BMDC TO FIBROSIS
The role of myofibroblasts in fibrosis is well-documented in
numerous solid tumors (Direkze et al., 2004), and along with
fibroblasts and ECM proteins they produce, are key components
of the desmoplastic response to tumors (De Wever and Mareel,
2003). Early studies by Direkze et al. (2004) demonstrated in a
mouse model of pancreatic insulinoma that BMDC contribute to
both myofibroblast and fibroblast populations within the tumors,
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FIGURE 1 | Bonemarrow derived cells contribute to the tumor
microenvironment following recruitment to the desmoplastic stroma and
differentiation into multiple cell types promoting tumor progression.
PanIN, pancreatic intraepithelial neoplasia; BMDC, bonemarrow-derived cells;
EPC, endothelial progenitor cells; MDSC, myeloid-derived suppressor cells;
PSC, pancreatic stellate cells; MSC, mesenchymal stem cells; FAP, fibroblast
activation protein-α; PDGF, platelet-derived growth factor; TGFβ1, transforming
growth factor beta 1; VEGF, vascular endothelial growth factor; BV, blood vessel.
particularly at the tumor margin. This study raised many ques-
tions, and suggested that the development of the pancreatic tumor
stroma may be a less localized phenomenon than first thought
(Direkze et al., 2004).
More recently, Lin et al. (2012) demonstrated in a mouse
model of caerulein-induced pancreatitis that circulating fibro-
cytes were indeed derived from BMDC. These fibrocytes could
engraft to the pancreas from peripheral circulation, and con-
tributed to pancreatic fibrosis in part by differentiating into
collagen-producing myofibroblasts. Further, when genetically
modifying the BMDC, the severity of the fibrosis within the pan-
creas could be altered, suggesting that BMDC can function as
fibrogenic cells (Lin et al., 2012).
CONTRIBUTION OF BMDC TO THE PANCREATIC STELLATE CELL
POPULATION
PSC are resident myofibroblast-like cells existing in the periaci-
nar space of the exocrine pancreas. In a healthy pancreas, PSC
(quiescent) comprise approximately 4% of pancreatic cells, and
exist in a periacinar dissemination. There is increasing evidence
to suggest that PSC are key participants in the pathogenesis of
pancreatic exocrine diseases, particularly in the production of the
abundant fibrous stroma, which is a feature of pancreatic cancer
(Apte et al., 1998, 2004; Bachem et al., 1998; Hwang et al., 2008;
Vonlaufen et al., 2008; Phillips, 2012).
Akita et al. (2012) demonstrated in a rat model of pancreatic
fibrosis that bone marrow derived activated PSC contribute to the
early stages of fibrosis, and produced the growth factors PDGF
and TGFβ1, key growth factors involved in the cross-talk between
pancreatic tumor cells and PSC that contribute to tumor invasion
and metastasis (Vonlaufen et al., 2008; Akita et al., 2012).
In a recent study investigating the potential role for BMDC
in pancreatic injury, regeneration and carcinogenesis, Scarlett
et al. (2011) observed that there was significant BMDC recruit-
ment to the inflammatory infiltrate at the time of pancreatic
injury (caerulein-induced chronic pancreatitis) consistent with
previous reports (Minami et al., 2005; Sparmann et al., 2010;
Scarlett et al., 2011), which was transient as cell numbers dimin-
ished over time to low levels when exocrine regeneration was
complete. Interestingly, PSC remained amongst the residual pop-
ulation of BMDC, suggesting that BMDC play a role in support-
ing the regenerative process, but do not transform to contribute
to the regenerative epithelium itself. As observed for chronic
pancreatitis, increased recruitment of BMDC to the pancreas
occurred following DMBA-induced carcinogenesis, which pre-
dominantly included inflammatory infiltrate, while activated PSC
were also present (Scarlett et al., 2011). In an earlier study,
Erkan et al. (2010) used transcript profiling to identify markers
to differentiate PSC associated with chronic pancreatitis against
those of pancreatic cancer, with the ultimate aim of subtyp-
ing PSC into either inflammation- or tumor-associated-PSC.
Erkan et al. identified Pre-B-cell leukemia transcription factor 1
(PBX1) to be upregulated in inflammation-associated PSC com-
pared to tumor-associated PSC, while cadherin EGF LAG seven-
pass G-type receptor 3 (CELSR3) expression was upregulated
in tumor-associated PSC compared to that of inflammation-
associated PSC (Erkan et al., 2010). In the study of Scarlett et al.
(2011), expression of CELSR3 in tumor-associated BMDC sug-
gests that there was modification of these PSC by the tumor
microenvironment, and that tumor associated BMDC PSC may
be retained in the peri-tumoral stroma, whilst those associated
with pancreatitis are not. This is supported by studies where bone
marrow-derived mesenchymal stem cells (MSC) preferentially
localize to regions of pancreatic tumor growth (Kallifatidis et al.,
2008) and have been shown to transform into tumor-associated
myofibroblasts in insulinomas (Direkze et al., 2004).
While most tumor associated activated PSC are thought to
arise from endogenous quiescent PSC, evidence now exists that
a proportion of these are bone marrow derived, and display
different phenotypes depending on whether they are recruited
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to an inflammatory or a carcinogenic pancreas. In pancreatic
carcinogenesis, and in chronic pancreatitis, BMDC contribute
significantly to the activated PSC population, with evidence sug-
gesting that this process occurs as an early event in pancreatic
carcinogenesis (Scarlett et al., 2011). Those associated with pan-
creatic cancer express genes characteristic of peritumoral stellate
cells as compared to those not associated with malignancy, pro-
viding further evidence that BMDC play an important role in
supporting pancreatic carcinogenesis, the mechanisms of which
remain to be elucidated.
Of interest are the mechanisms by which BMDC are recruited
to the stroma. Are they recruited by resident PSC themselves?
Or do they migrate to regions of fibrosis via inflammatory sig-
naling? Or both? Within the early stages of pancreatic injury,
resident quiescent PSC become activated and promote fibrosis
via the expression of ECM proteins, cytokines and growth fac-
tors such as PDGF and TGFβ1. These growth factors are known
activators of PSC and in an autocrine manner leads to persis-
tent PSC activation, promoting further fibrosis. A consequence
of fibrosis is the increased recruitment of BMDC to the stroma,
including BM derived PSC (Akita et al., 2012). This suggests a
role for tissue repair, however, depending on the signals that the
migrating BMDC receive (such as those observed in a tumor-
associated microenvironment), this may lead to an environment
supporting tumor progression as opposed to tissue repair, as
described above (Erkan et al., 2010) and [reviewed in (Evans
and Costello, 2012)]. Clearly there is more complexity involved
than just an inflammation, PSC activation, BMDC recruitment
and differentiation loop occurring in the fibrotic microenviron-
ment. Delineating the exact mechanisms by which this occurs
will lead to novel therapeutic strategies targeting the fibrotic
stroma.
CONTRIBUTION OF BMDC TO IMMUNOSUPPRESSION
It is long known that inflammation is crucially linked to pan-
creatic cancer development, as evidenced by chronic pancreatitis
being a major risk factor (Lowenfels et al., 1993). The mech-
anisms by which inflammation exacerbates an individual’s risk
of developing pancreatic cancer are yet to be fully understood.
It is becoming increasingly evident that immune cells make up
approximately 50% of the tumor mass (tumor and stroma) (Clark
et al., 2007; Scarlett et al., 2011), with immunosuppressive cells,
such as Myeloid-derived suppressor cells (MDSC) and mast cells,
predominant.
Myeloid-derived suppressor cells (MDSC)
MDSC are a heterogeneous population of undifferentiated and
immature myeloid immunosuppressive cells. Tumor-induced
alterations in bone-marrow myelopoiesis are driven by growth
factors and cytokines secreted by the tumor, which leads to expan-
sion and mobilization of MDSC. Once mobilized to the stroma,
MDSC promotes tumor growth, invasion, and tumor-induced
immunosuppression and host immune evasion by inhibiting lym-
phocyte activation and antigen recognition (Serafini et al., 2006;
Marigo et al., 2008; Gabrilovich and Nagaraj, 2009). Of impor-
tance, Porembka et al. (2012) recently demonstrated that patients
with pancreatic adenocarcinoma exhibited increased MDSC in
the bone marrow and peripheral circulation, as well as within the
tumor itself, while inhibition of MDSC with the aminobisphos-
phonate zoledronic acid, reduces intra-tumoral accumulation of
MDSC preventing tumor growth and increasing T-cell recruit-
ment (Porembka et al., 2012).
Mast cells
Mast cells regulate adaptive immune responses via the release of
cytokines and other immunomodulatory factors, which promote
immune suppression and potentially tumor progression (Galli
et al., 2005; Kalesnikoff and Galli, 2008). Chang et al. (2011)
demonstrated that migration of bone-marrow derived mast cells
to the tumor microenvironment is an early event in carcinogene-
sis and is necessary for tumor growth, the mechanisms of which
remain to be elucidated (Chang et al., 2011).
The importance of an additional immunosuppressive cell type
within the stroma was further defined through a recent study by
Kraman et al. (2010), who demonstrated that a sub-population of
stromal cells that express fibroblast activation protein (FAP) sup-
press the immune response and that abrogation of FAP expression
arrests the growth of pancreatic tumors, potentially by removing
their inhibitory effect on the host’s immune response. (Kraman
et al., 2010; Schreiber and Rowley, 2010). Thus, novel immunos-
timulatory therapeutic strategies targeting these immunosup-
pressive mechanisms may prove effective against pancreatic
adenocarcinomas.
CONTRIBUTION OF BMDC TO NEOVASCULARIZATION
A consequence of the excessive desmoplastic stroma is a profound
alteration of the tumor vasculature, with the subsequent vascu-
lar dysfunction presenting a significant barrier to the delivery of
chemotherapeutic agents to the tumor cells. As such, strategies
targeting elements within the stroma have become more exten-
sively studied (Olive et al., 2009; Provenzano et al., 2012). The
mysteries surrounding hypovascularity in pancreatic cancer have
been reviewed elsewhere (Feig et al., 2012), with many questions
remaining unanswered at present. This section will focus solely
on the contribution of BMDC to tumor neovascularization, and
the implications therein.
Most solid tumors require a vascular supply to provide oxygen
and nutrients to enhance tumor progression and invasion. The
tumor can either exploit existing vessels, or recruit and mobilize
BMDC to induce neovascularization. BMDC are increasingly val-
ued to be important contributors to the expansion of the tumor
vasculature, however, the mechanisms of BMDC recruitment
and mobilization by the tumors are yet to be fully understood
(Lyden et al., 2001; Shojaei et al., 2007; Chan et al., 2009).
Endothelial progenitor cells (EPCs) originate from BMDC
and possess the capacity to differentiate into mature endothe-
lial cells, contributing to the complex process of tumor neo-
vascularization. There is evidence that tumor angiogenesis can
be stimulated by tumor cell secreted CXC chemokine ligands
CXCL5 and CXCL8, via their common receptor CXCR2 (Wente
et al., 2006; Raman et al., 2007). Li et al. (2011) recently
demonstrated a role for BM-derived EPCs in stimulating neo-
vascularization and pancreatic cancer growth, with EPCs mobi-
lized by the pancreatic cancer cells, and that targeting the
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CXCL5/CXCL8/CXCR2 axis impaired EPC mobilization, prolif-
eration, differentiation and neovascularization. CXCR2 in partic-
ular was required for EPC mobilization during pancreatic tumor
growth, indicating a critical role for CXCR2 in the regulation of
BM-derived progenitor cells with respect to tumor angiogenesis
(Li et al., 2011).
BM-derived MSC have also been shown to migrate toward
tumor hypoxia-induced secretion of growth factors (VEGF,
PDGF, EGF) in pancreatic tumors, and contribute to neovas-
cularization by homing to fast growing tumors and incorpo-
rating into blood vessels as atypical VEGF-secreting endothelial
cells (Beckermann et al., 2008). For pancreatic cancer in par-
ticular, anti-vascular therapies have failed to show a survival
benefit, most likely due to the heterogeneous tumor microen-
vironment that creates a hypovascular milieu. It is clear that
the tumor microenvironment plays a critical role in pancreatic
tumor development and progression and that circulating BMDC
have an inherent capacity to differentiate into endothelial cells to
form new vasculature (Gao et al., 2008a). Recently, Nakamura
et al. (2010) identified that BM-derived pro-angiogenic cells are
potential targets for Sonic Hedgehog (Shh), derived from the
pancreatic tumors, and that Hh blockade can disrupt tumor
angiogenesis in vivo, which is mediated through the impaired
interaction BMDC with the neovasculature in pancreatic cancer
(Nakamura et al., 2010). As such, it was speculated that induction
of angiogenesis via Shh may mediate VEGF-independent neo-
vascularization in pancreatic cancer, thereby serving as a poten-
tial mechanism for resistance to anti-VEGF therapy (Mizukami,
2012).
There is mounting evidence that BMDC contribute to the
neovascularization in pancreatic cancer, however, pancreatic can-
cer remains a hypovascular tumor with significant perfusion
impairment. With a distinct lack of efficacy of anti-angiogenic
therapies for pancreatic cancer [reviewed in (Feig et al., 2012)],
alternative approaches targeting the pancreatic cancer vasculature
are required.
CONCLUDING REMARKS
In conclusion, pancreatic carcinogenesis is an extremely aggres-
sive, and complex malignancy with very few effective therapeutic
modalities. Pancreatic cancer is characterized by an extensive
desmoplastic stroma that interacts with the tumor cells, where
together they drive tumor progression, invasion and metastasis.
In addition, the stroma provides a physical barrier, denying the
tumor cells access to chemotherapeutic agents. Future research
priorities should be focused on further understanding the com-
plex tumor-stroma relationships, which is key for facilitating
the development of potential novel therapeutic strategies. Such
strategies may include reducing tumor neovascularization by tar-
geting the ablation of BM derived EPC (Li et al., 2011); or
genetic manipulation of (1) BMDC to block Hh signaling and
regress the tumor vasculature (Nakamura et al., 2010), or (2) BM
derived PSC by using the hGFAP promotor to develop targeted
gene/drug therapy (Ding et al., 2009); or by unmasking the host’s
immune response by targeting BMD stromal fibroblasts that con-
tribute to immunosuppression and tumor progression (Kraman
et al., 2010). This review discussed the role of BMDC in pancre-
atic carcinogenesis, in particular their contribution to the tumor
microenvironment, where they play a significant role in fibro-
sis, immunosuppression and neovascularization, and may pro-
vide opportunities for novel therapeutic strategies for pancreatic
cancer.
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